Dave Feldman

Dave Feldman and Dr. William Cromwell dive deep into the safety of high cholesterol on a keto diet. They discuss the lipid hypothesis, ApoB's role in atherosclerosis, interpreting mortality data, and the complexities of plaque formation. The conversation challenges traditional views on lipidology, explores biomarkers, gut health supplements, and macrophage involvement. They also touch on longevity habits, research design for hyper-responders, managing high cholesterol levels, and analyzing plaque risk in different diet contexts.

Join experts Dave Feldman and Dr. William Cromwell as they debate high cholesterol risks on a ketogenic diet. Unpack lipid hypotheses, ApoB's role, mortality factors, and metabolic vulnerability. Explore cholesterol levels' impacts on atherosclerosis and the complexities of statin therapy for managing high LDL cholesterol.

In this engaging discussion, Dave Feldman, an engineer and CEO of the Citizen Science Foundation, challenges conventional wisdom about LDL cholesterol. He reveals fascinating insights from his latest study, showing that lean mass hyper-responders on ketogenic diets can exhibit elevated LDL without increased heart disease risk. The conversation delves into the importance of ApoB over LDL, the complexities of cardiovascular health, and the necessity for individualized risk assessments. Feldman's work encourages a reevaluation of how we view cholesterol in relation to metabolic health.

Topics include debunking health myths around high LDL cholesterol, the impact of ketogenic diets on cholesterol levels, the Oreo experiment challenging traditional perspectives, the nuances of LDL and plaque formation, and the impact of diets on LDL cholesterol levels.

Dave Feldman, a researcher studying LDL and cardiovascular risk, joins Paul Saladino on the podcast. They discuss a recent study about LDL and cardiovascular risk, the response from the medical community, and the role of credentials in online discussions. They also explore the risks and benefits of lipid-lowering therapies like statins and the effects of ketogenic and low carb diets on LDL cholesterol levels.

David Feldman is an engineer who initiated the Citizen Science Foundation dedicated to advancing citizen science in the field of cholesterol and lipid research.  He has become a well respected figure on the subject of cholesterol. He discusses his recent involvment in a ground breaking study involving "lean mass hyper responders".  So, is a high LDL cholesterol bad in someone eating a low carb diet?  Listen as Dave unpacks the research. Connect with Dave atCholesterol Code: https://cholesterolcode.comCitizen Science Foundation: https://citizensciencefoundation.org/Own Your Labs: https://ownyourlabs.com/Twitter: https://twitter.com/realDaveFeldmanContact Dr. Greg at:vibrantlifedc.com

Dave Feldman, Dr. Nick Norwitz & Dr. Dominic D’Agostino discuss the lean mass hyper-responder phenotype, Oreo vs statin study, role of exercise, alarming LDL levels, gym hypothesis, and the need for further research on ketogenic diets and cholesterol impact on health.

Join citizen scientist Dave Feldman, founder of the Citizen Science Foundation, and Nick Norwitz, an Oxford PhD and Harvard medical student, as they challenge traditional views on LDL cholesterol and heart health. They discuss their research on lean mass hyper-responders, revealing that LDL levels might not correlate with plaque buildup in keto dieters. The duo also highlights how advanced imaging techniques could redefine cardiovascular risk assessment, pushing for a fresh perspective on cholesterol management and dietary impacts on long-term health.

In this episode, Dave Feldman, discusses his journey from software engineer to n=1 experimenter, his experience with low-carbohydrate diets, and his hypothesis that cholesterol levels are influenced by energy metabolism.   We discuss: Peter’s synthesis of Dave’s energy model [5:00]; Dave’s journey from software engineer to cholesterol enthusiast [15:00]; Standard blood panels, sterol panels, and what moves the needle when it comes to particle numbers [18:30]; Hyper-responders [20:00]; Lipoprotein transport [33:45]; The lean mass hyper-responder phenotype [47:30]; The progression of atherosclerosis, CAC, and CIMT [52:30]; Testing for oxidized LDL [55:30]; All-cause mortality and clinical endpoints [1:01:15]; What does “LDL as causal” mean? [1:05:15]; Dave’s low carb cholesterol challenge and drug & genetic study qualifications [1:13:15]; If all other markers are in an healthy range, but LDL-P is high, is the patient at risk? A couple of case studies, and a self-experiment [1:27:30]; Peter’s three-day exercise and ketosis experiment [1:41:00]; What are remnant lipoproteins? [1:45:00]; What might cause lean mass hyper-responders to have higher LDL particle numbers? [1:53:30]; A case study from Dave of a lean mass hyper-responder [1:56:30]; Mass balance and cholesterol flux [2:05:30]; Can a higher degree of cholesterol explain the lean mass hyper-responder phenotype? [2:10:00]; Peter’s LDL during his keto-fast-keto experiment [2:13:30]; Does substituting saturated fats with monounsaturated fats lower LDL-P and LDL-C? [2:15:45]; Dave’s carb-swap experiments [2:22:15]; Dave’s carotid intima-media thickness tests [2:41:15]; Looking for studies that stratify for high HDL-C and low TG alongside low and high LDL-C [2:53:00]; and More Learn more at www.PeterAttiaMD.com Connect with Peter on Facebook | Twitter | Instagram.

Dave Feldman, an engineer known for his research on lean mass hyper-responders, Nick Norwitz, a human metabolism PhD from Oxford studying at Harvard, and Adrian Sotomata, a physician internist with an Oxford PhD, challenge conventional wisdom about LDL cholesterol. They discuss how high LDL levels don’t always indicate cardiovascular risk, emphasizing the importance of personalized health strategies and lifestyle choices. The conversation critiques traditional lipid management, explores the complexity of dietary influences, and highlights the need for nuanced approaches to health.